NephroPlus delivered another strong quarter with 24% revenue growth, 31% EBITDA growth and 42% PAT growth, while EBITDA margins expanded by 120 bps YoY. Group CFO Prashant Goenka explains the key operating levers behind the performance.
The company is seeing increasing contribution from its international business, with higher revenue per treatment in markets such as the Philippines and Uzbekistan helping drive operating leverage. NephroPlus is also expanding its footprint in India and overseas, with Saudi Arabia and Kazakhstan emerging as potential growth markets.
The conversation covers clinic expansion, Philippines acquisitions, revenue per treatment, ECL provisions, margins and the outlook for international growth.
#etnow #nephroplus #nephroplusresults #healthcarestocks #healthcareindia #dialysis #stockmarketindia #q1results #indianstockmarket
YouTube Channel – https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC
Website – https://www.etnownews.com
Download our App for Breaking News: https://tinyurl.com/4y6e3u2e
Follow us on Google News for latest updates
ET Now: https://news.google.com/publications/CAAqBwgKMK3HxQsw0OLcAw?hl=en-IN&gl=IN&ceid=IN%3Aen
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
source
